Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with ...(al of Cloretazine(R) (VNP40101M)as a sin...),Health

Date:5/8/2008

al of Cloretazine(R) (VNP40101M) as a single agent." Ms. Cahill concluded, "Cloretazine(R) (VNP40101M) has shown activity in AML and MDS, warranting further study in the treatment of these devastating conditions as both a single agent and in combination with other therapies."

Dr. Ritchie commented, "We are enthusiastic to begin exploring this regimen for AML and MDS patients that are over the age of 60. As standard therapies for these individuals have shown to be inadequate, there exists a need for our continued attention to research and development of new treatment options. Preliminary clinical trials using Cloretazine(R) (VNP40101M) in combination with cytarabine have demonstrated favorable activity and compelling evidence for further study. The knowledge gained from this research study will bring us closer to our goal of finding the best possible treatment for our patients that will extend the length as well as improve the quality of their lives."

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statemen
'/>"/>

SOURCE Vion Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
2. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
3. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
4. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
5. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
6. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
7. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
8. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
9. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
10. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
11. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results